Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies, presents a poster with promising preclinical data on a novel viral vector (pseudocowpox, PCPV) at the AACR (American Association for Cancer Research) Annual Meeting 2018, Chicago, IL, USA, April 14 – 18.
PCPV was found to be the most promising therapeutic candidate amongst the poxviridae evaluated by Transgene:
The abstract is available on the AACR 2018 website (#LB-287) and will be published in Cancer Research in June 2018.
Poster title: Pseudocowpox: A next generation viral vector for cancer immunotherapy. A poxviral vector selected for its remarkable ability to induce IFN-alpha.
- End -
Notes to editors
About Transgene
Transgene
(Euronext: TNG), part of Institut Mérieux, is a publicly traded French
biotechnology company focused on designing and developing targeted
immunotherapies for the treatment of cancer and infectious diseases.
Transgene’s programs utilize viral vector technology with the goal of
indirectly or directly killing infected or cancerous cells. The
Company’s lead clinical-stage programs are: TG4010, a therapeutic
vaccine against non-small cell lung cancer, Pexa-Vec, an oncolytic virus
against liver cancer, and TG4001, a therapeutic vaccine against
HPV-positive head and neck cancers. The Company has several other
programs in clinical development, including TG1050 (chronic hepatitis B)
and TG6002 (solid tumors).
With its proprietary Invir.IOTM,
Transgene builds on its expertise in viral vectors engineering to design
a new generation of multifunctional oncolytic viruses.
Transgene is
based in Strasbourg, France, and has additional operations in Lyon, as
well as a joint venture in China. Additional information about Transgene
is available at www.transgene.fr.
Follow
us on Twitter: @TransgeneSA
Disclaimer
This press release contains
forward-looking statements, which are subject to numerous risks and
uncertainties, which could cause actual results to differ materially
from those anticipated. There can be no guarantee that (i) the results
of pre-clinical work and prior clinical trials will be predictive of the
results of the clinical trials currently underway, (ii) regulatory
authorities will agree with the Company’s further development plans for
its therapies, or (iii) the Company will find development and
commercialization partners for its therapies in a timely manner and on
satisfactory terms and conditions, if at all. The occurrence of any of
these risks could have a significant negative outcome for the Company’s
activities, perspectives, financial situation, results and development.
For
a discussion of risks and uncertainties which could cause the Company's
actual results, financial condition, performance or achievements to
differ from those contained in the forward-looking statements, please
refer to the Risk Factors (“Facteurs de Risques”) section of the
Document de Référence, available on the AMF website (http://www.amf-france.org)
or on Transgene’s website (www.transgene.fr).
Forward-looking statements speak only as of the date on which they are
made, and Transgene undertakes no obligation to update these
forward-looking statements, even if new information becomes available in
the future.
View source version on businesswire.com:
Transgene:
Lucie Larguier, +33 (0)3 88 27 91 04
Director
Corporate Communications & IR
investorrelations@transgene.fr
or
Media:
Citigate
Dewe Rogerson
David Dible/Marine Perrier, + 44 (0)20 7638 9571
transgene@citigatedewerogerson.com